Company intelligence / Profile preview

Prevent-Plus

St. Louis, Missouri, USApreventogen.com ↗

Ownership: Private
Development stage: Other

Overview

Preventogen, the flagship product of Prevent‑Plus, is an FDA-cleared hospital-grade liquid polymer that provides both microbicidal action and a physical barrier to prevent infections. Recent clinical studies showed zero surgical site infections in elective surgery patients treated with Preventogen compared to an expected 4.13% rate, and zero exit-site or catheter-related bloodstream infections over 9,927 catheter days in hemodialysis patients—significantly outperforming historical controls. The product is supported by strong scientific data demonstrating efficacy across various wound types.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: DevicePolymer-based barrier technology (liquid polymer for infection prevention)
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on Prevent-Plus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prevent-Plus.

Explore the full profile